» Articles » PMID: 28549433

JS-K, a Nitric Oxide Pro-drug, Regulates Growth and Apoptosis Through the Ubiquitin-proteasome Pathway in Prostate Cancer Cells

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2017 May 28
PMID 28549433
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In view of the fact that JS-K might regulate ubiquitin E3 ligase and that ubiquitin E3 ligase plays an important role in the mechanism of CRPC formation, the goal was to investigate the probable mechanism by which JS-K regulates prostate cancer cells.

Methods: Proliferation inhibition by JS-K on prostate cancer cells was examined usingCCK-8 assays. Caspase 3/7 activity assays and flow cytometry were performed to examine whether JS-K induced apoptosis in prostate cancer cells. Western blotting and co-immunoprecipitation analyses investigated JS-K's effects on the associated apoptosis mechanism. Real time-PCR and Western blotting were performed to assess JS-K's effect on transcription of specific AR target genes. Western blotting was also performed to detect Siah2 and AR protein concentrations and co-immunoprecipitation to detect interactions of Siah2 and AR, NCoR1 and AR, and p300 and AR.

Results: JS-K inhibited proliferation and induced apoptosis in prostate cancer cells. JS-K increased p53 and Mdm2 concentrations and regulated the caspase cascade reaction-associated protein concentrations. JS-K inhibited transcription of AR target genes and down-regulated PSA protein concentrations. JS-K inhibited Siah2 interactions and also inhibited the ubiquitination of AR. With further investigation, JS-K was found to stabilize AR and NCoR1 interactions and diminish AR and p300 interactions.

Conclusions: The present results suggested that JS-K might have been able to inhibit proliferation and induce apoptosis via regulation of the ubiquitin-proteasome degradation pathway, which represented a promising platform for the development of new compounds for PCa treatments.

Citing Articles

JS-K activates G2/M checkpoints through the DNA damage response and induces autophagy via CAMKKβ/AMPKα/mTOR pathway in bladder cancer cells.

Zhao Y, Lin S, Zeng W, Lin X, Qin X, Miu B J Cancer. 2024; 15(2):343-355.

PMID: 38169515 PMC: 10758033. DOI: 10.7150/jca.86393.


Functional roles of E3 ubiquitin ligases in prostate cancer.

Zhao Y, Li J, Chen J, Ye M, Jin X J Mol Med (Berl). 2022; 100(8):1125-1144.

PMID: 35816219 DOI: 10.1007/s00109-022-02229-9.


Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Salihi A, Al-Naqshabandi M, Khudhur Z, Housein Z, Hama H, Abdullah R Mol Med Rep. 2022; 26(1).

PMID: 35616143 PMC: 9178674. DOI: 10.3892/mmr.2022.12749.


A review of the relatively complex mechanism of JS-K induced apoptosis in cancer cells.

Tan G, Wu A, Li Z, Awasthi P Transl Cancer Res. 2022; 8(4):1602-1608.

PMID: 35116903 PMC: 8797525. DOI: 10.21037/tcr.2019.07.20.


S-Nitrosylation in Tumor Microenvironment.

Sharma V, Fernando V, Letson J, Walia Y, Zheng X, Fackelman D Int J Mol Sci. 2021; 22(9).

PMID: 33925645 PMC: 8124305. DOI: 10.3390/ijms22094600.


References
1.
Lecker S, Goldberg A, Mitch W . Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 2006; 17(7):1807-19. DOI: 10.1681/ASN.2006010083. View

2.
Yu Z, Geyer R, Maki C . MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 2000; 19(51):5892-7. DOI: 10.1038/sj.onc.1203980. View

3.
Udupi V, Yu M, Malaviya S, Saavedra J, Shami P . JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. Leuk Res. 2006; 30(10):1279-83. DOI: 10.1016/j.leukres.2005.12.007. View

4.
Um H, Jang J, Kim D, Lee C, Surh Y . Nitric oxide activates Nrf2 through S-nitrosylation of Keap1 in PC12 cells. Nitric Oxide. 2011; 25(2):161-8. DOI: 10.1016/j.niox.2011.06.001. View

5.
Shami P, Saavedra J, Wang L, Bonifant C, Diwan B, Singh S . JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther. 2003; 2(4):409-17. View